ASX:CUV

Stock Analysis Report

Executive Summary

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of severe genetic and skin disorders in Europe, the United States, and Singapore.

Snowflake

Fundamentals

Flawless balance sheet with high growth potential.

Share Price & News

How has Clinuvel Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-15.7%

CUV

5.1%

AU Biotechs

2.5%

AU Market


1 Year Return

62.1%

CUV

32.2%

AU Biotechs

11.1%

AU Market

Return vs Industry: CUV exceeded the Australian Biotechs industry which returned 32.2% over the past year.

Return vs Market: CUV exceeded the Australian Market which returned 11.1% over the past year.


Shareholder returns

CUVIndustryMarket
7 Day-15.7%5.1%2.5%
30 Day29.6%9.9%0.7%
90 Day3.7%13.5%1.4%
1 Year62.2%62.1%33.8%32.2%17.5%11.1%
3 Year368.4%367.5%145.8%136.9%37.8%19.4%
5 Year1137.2%1134.7%238.1%216.2%51.7%17.6%

Price Volatility Vs. Market

How volatile is Clinuvel Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Clinuvel Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

20.7%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: CUV (A$32.35) is trading below our estimate of fair value (A$40.79)

Significantly Undervalued: CUV is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: CUV is poor value based on its PE Ratio (86x) compared to the Biotechs industry average (29.4x).

PE vs Market: CUV is poor value based on its PE Ratio (86x) compared to the Australian market (18x).


Price to Earnings Growth Ratio

Low PEG Ratio: CUV is poor value based on its PEG Ratio (6x)


Price to Book Ratio

PB vs Industry: CUV is overvalued based on its PB Ratio (27.7x) compared to the AU Biotechs industry average (3.1x).


Next Steps

Future Growth

How is Clinuvel Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

14.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CUV's forecast earnings growth (14.4% per year) is above the savings rate (2.3%).

Earnings vs Market: CUV's earnings (14.4% per year) are forecast to grow faster than the Australian market (10.3% per year).

High Growth Earnings: CUV's earnings are forecast to grow, but not significantly.

Revenue vs Market: CUV's revenue (41.4% per year) is forecast to grow faster than the Australian market (3.6% per year).

High Growth Revenue: CUV's revenue (41.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: CUV's Return on Equity is forecast to be high in 3 years time (27.3%)


Next Steps

Past Performance

How has Clinuvel Pharmaceuticals performed over the past 5 years?

70.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: CUV has become profitable over the past 5 years, growing earnings by 70.5% per year.

Accelerating Growth: CUV's earnings growth over the past year (37.1%) is below its 5-year average (70.5% per year).

Earnings vs Industry: CUV earnings growth over the past year (37.1%) exceeded the Biotechs industry 16.2%.


Return on Equity

High ROE: CUV's Return on Equity (31.7%) is considered high.


Return on Assets

ROA vs Industry: CUV has a higher Return on Assets than the Biotechs industry average last year.


Return on Capital Employed

ROCE Improving: CUV's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is Clinuvel Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: CUV's short term assets (A$61.2M) exceeds its short term liabilities (A$5.0M)

Long Term Liabilities: CUV's short term assets (61.2M) exceeds its long term liabilities (205.5K)


Debt to Equity History and Analysis

Debt Level: CUV is debt free.

Reducing Debt: CUV has not had any debt for past 5 years.

Debt Coverage: CUV has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: CUV has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: CUV has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if CUV's debt is covered by short term assets.


Next Steps

Dividend

What is Clinuvel Pharmaceuticals's current dividend yield, its reliability and sustainability?

0.077%

Current Dividend Yield


Dividend Yield vs Market

company0.08%marketbottom25%2.5%markettop25%5.6%industryaverage2.0%forecastin3Years0.04%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: CUV's dividend (0.077%) isn’t notable compared to the bottom 25% of dividend payers in the Australian market (2.46%).

High Dividend: CUV's dividend (0.077%) is low compared to the top 25% of dividend payers in the Australian market (5.56%).

Stable Dividend: CUV is not paying a notable dividend for the Australian market, therefore no need to check if payments are stable.

Growing Dividend: CUV is not paying a notable dividend for the Australian market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: CUV is not paying a notable dividend for the Australian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CUV's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

What is the CEO of Clinuvel Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

13.8yrs

Average management tenure


CEO

Philippe Wolgen (56yo)

13.9yrs

Tenure

AU$1,415,126

Compensation

Dr. Philippe Jacques Wolgen, MBA, M.D., has been the Chief Executive Officer and Managing Director of Clinuvel Pharmaceuticals Limited since November 28, 2005 to lead the corporate turnaround of the Group. ...


CEO Compensation Analysis

Compensation vs. Market: Philippe's total compensation ($USD955.39K) is about average for companies of similar size in the Australian market ($USD980.46K).

Compensation vs Earnings: Philippe's compensation has been consistent with company performance over the past year.


Management Age and Tenure

13.8yrs

Average Tenure

Experienced Management: CUV's management team is seasoned and experienced (13.8 years average tenure).


Board Age and Tenure

8.3yrs

Average Tenure

67yo

Average Age

Experienced Board: CUV's board of directors are considered experienced (8.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Philippe Wolgen (56yo)

    CEO, MD & Director

    • Tenure: 13.9yrs
    • Compensation: AU$1.42m
  • Dennis Wright

    Acting Chief Scientific Officer

    • Tenure: 7.1yrs
    • Compensation: AU$296.35k
  • Darren Keamy (46yo)

    CFO & Company Secretary

    • Tenure: 13.8yrs
    • Compensation: AU$336.50k
  • Lachlan Hay

    General Manager of Europe

    • Tenure: 0yrs
  • Malcolm Bull

    Head of Investor Relations

    • Tenure: 0yrs

Board Members

  • Stan McLiesh (82yo)

    Non-Executive Chairman

    • Tenure: 11.8yrs
    • Compensation: AU$112.52k
  • Brenda Shanahan

    Non-Executive Director

    • Tenure: 12.7yrs
    • Compensation: AU$82.52k
  • Philippe Wolgen (56yo)

    CEO, MD & Director

    • Tenure: 13.9yrs
    • Compensation: AU$1.42m
  • Sue Smith

    Non-Executive Director

    • Tenure: 0.08yrs
  • Willem Blijdorp (67yo)

    Non-Executive Director

    • Tenure: 4.8yrs
    • Compensation: AU$80.00k
  • Karen Agersborg

    Non-Executive Director

    • Tenure: 1.8yrs
    • Compensation: AU$65.00k

Company Information

Clinuvel Pharmaceuticals Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Clinuvel Pharmaceuticals Limited
  • Ticker: CUV
  • Exchange: ASX
  • Founded: 1999
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$1.658b
  • Shares outstanding: 48.96m
  • Website: https://www.clinuvel.com

Location

  • Clinuvel Pharmaceuticals Limited
  • 535 Bourke Street
  • Level 11
  • Melbourne
  • Victoria
  • 3000
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
UR9DB (Deutsche Boerse AG)YesOrdinary SharesDEEURFeb 2001
CUVASX (Australian Securities Exchange)YesOrdinary SharesAUAUDFeb 2001
CLVL.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDFeb 2001
CUVCHIA (Chi-X Australia)YesOrdinary SharesAUAUDFeb 2001
CLVL.YOTCPK (Pink Sheets LLC)SPON ADR EA REP 1 ORD NPVUSUSDMay 2004
UR9ADB (Deutsche Boerse AG)SPON ADR EA REP 1 ORD NPVDEEURMay 2004

Biography

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of severe genetic and skin disorders in Europe, the United States, and Singapore. Its lead drug  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 10:32
End of Day Share Price2019/10/17 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.